{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:56:30Z","timestamp":1777906590749,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["260353"],"award-info":[{"award-number":["260353"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"name":"IRCCS Istituto Giannina Gaslini"},{"DOI":"10.13039\/501100001826","name":"ZonMW","doi-asserted-by":"publisher","award":["PharmachildNL 80-83600-98-21012"],"award-info":[{"award-number":["PharmachildNL 80-83600-98-21012"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Etanercept (ETN) and adalimumab (ADA) are considered equally effective biologicals in the treatment of arthritis in juvenile idiopathic arthritis (JIA) but no studies have compared their impact on patient-reported well-being. The objective of this study was to determine whether ETN and ADA have a differential effect on patient-reported well-being in non-systemic JIA using real-world data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Biological-naive patients without a history of uveitis were selected from the international Pharmachild registry. Patients starting ETN were matched to patients starting ADA based on propensity score and outcomes were collected at time of therapy initiation and 3\u201312\u00a0months afterwards. Primary outcome at follow-up was the improvement in Juvenile Arthritis Multidimensional Assessment Report (JAMAR) visual analogue scale (VAS) well-being score from baseline. Secondary outcomes at follow-up were decrease in active joint count, adverse events and uveitis events. Outcomes were analyzed using linear and logistic mixed effects models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of 158 eligible patients, 45 ETN starters and 45 ADA starters could be propensity score matched resulting in similar VAS well-being scores at baseline. At follow-up, the median improvement in VAS well-being was 2 (interquartile range (IQR): 0.0 \u2013 4.0) and scores were significantly better (<jats:italic>P<\/jats:italic>\u2009=\u20090.01) for ETN starters (median 0.0, IQR: 0.0 \u2013 1.0) compared to ADA starters (median 1.0, IQR: 0.0 \u2013 3.5). The estimated mean difference in VAS well-being improvement from baseline for ETN versus ADA was 0.89 (95% CI: -0.01 \u2013 1.78; <jats:italic>P<\/jats:italic>\u2009=\u20090.06). The estimated mean difference in active joint count decrease was -0.36 (95% CI: -1.02 \u2013 0.30; <jats:italic>P<\/jats:italic>\u2009=\u20090.28) and odds ratio for adverse events was 0.48 (95% CI: 0.16 \u20131.44; <jats:italic>P<\/jats:italic>\u2009=\u20090.19). One uveitis event was observed in the ETN group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Both ETN and ADA improve well-being in non-systemic JIA. Our data might indicate a trend towards a slightly stronger effect for ETN, but larger studies are needed to confirm this given the lack of statistical significance.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-022-00763-x","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T16:20:12Z","timestamp":1668442812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8766-6694","authenticated-orcid":false,"given":"Joeri W.","family":"van Straalen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sytze","family":"de Roock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Giancane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Consolaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marite","family":"Rygg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen B.","family":"Nordal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadina","family":"Rubio-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Jelusic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"De Inocencio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Vojinovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nico M.","family":"Wulffraat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia C. J.","family":"Bruijning-Verhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolino","family":"Ruperto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost F.","family":"Swart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Paediatric Rheumatology International Trials Organisation (PRINTO)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Pallotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Scala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Angioloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Villa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"763_CR1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","volume":"81","author":"S Thierry","year":"2014","unstructured":"Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: A systematic review. Jt Bone Spine. 2014;81:112\u20137.","journal-title":"Jt. Bone Spine."},{"key":"763_CR2","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369:767\u201378.","journal-title":"Lancet"},{"key":"763_CR3","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","volume":"377","author":"B Prakken","year":"2011","unstructured":"Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377:2138\u201349.","journal-title":"Lancet"},{"key":"763_CR4","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390\u20132.","journal-title":"J Rheumatol"},{"key":"763_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/art.42037","volume":"74","author":"KB Onel","year":"2022","unstructured":"Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2022;74:553\u201369 (John Wiley and Sons Inc).","journal-title":"Arthritis Rheumatol"},{"key":"763_CR6","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.autrev.2017.07.014","volume":"16","author":"R Cimaz","year":"2017","unstructured":"Cimaz R, Marino A, Martini A. How I treat juvenile idiopathic arthritis: A state of the art review. Autoimmun Rev Elsevier. 2017;16:1008\u201315.","journal-title":"Autoimmun Rev Elsevier"},{"key":"763_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12098-015-1966-1","volume":"83","author":"V Viswanathan","year":"2016","unstructured":"Viswanathan V, Murray KJ. Management of Children with Juvenile Idiopathic Arthritis. Indian J Pediatr Springer India. 2016;83:63\u201370.","journal-title":"Indian J Pediatr Springer India"},{"key":"763_CR8","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.berh.2018.01.001","volume":"31","author":"G Giancane","year":"2017","unstructured":"Giancane G, Alongi A, Rosina S, Tibaldi J, Consolaro A, Ravelli A. Recent therapeutic advances in juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol. 2017;31:476\u201387 (Bailli\u00e8re Tindall).","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"763_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12969-016-0088-2","volume":"14","author":"SLN Clarke","year":"2016","unstructured":"Clarke SLN, Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol. 2016;14:27 (BioMed Central).","journal-title":"Pediatr Rheumatol"},{"key":"763_CR10","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1093\/rheumatology\/ket170","volume":"52","author":"J Anink","year":"2013","unstructured":"Anink J, Otten MH, Gorter SL, Prince FHM, van Rossum MAJ, van den Berg JM, et al. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab? Rheumatology. 2013;52:1674\u20139 (Narnia).","journal-title":"Rheumatology"},{"key":"763_CR11","doi-asserted-by":"publisher","unstructured":"Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819\u201328. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213030.","DOI":"10.1136\/annrheumdis-2018-213030"},{"key":"763_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12969-019-0370-1","volume":"17","author":"M Tarkiainen","year":"2019","unstructured":"Tarkiainen M, Tynj\u00e4l\u00e4 P, V\u00e4h\u00e4salo P, Kr\u00f6ger L, Aalto K, Lahdenne P. Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial. Pediatr Rheumatol. 2019;17:80 (BioMed Central).","journal-title":"Pediatr Rheumatol"},{"key":"763_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/acr.23236","volume":"70","author":"K Oen","year":"2018","unstructured":"Oen K, Guzman J, Dufault B, Tucker LB, Shiff NJ, Duffy KW, et al. Health-Related Quality of Life in an Inception Cohort of Children With Juvenile Idiopathic Arthritis: A Longitudinal Analysis. Arthritis Care Res (Hoboken). 2018;70:134\u201344 (John Wiley & Sons, Ltd).","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"763_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12969-016-0085-5","volume":"14","author":"A Consolaro","year":"2016","unstructured":"Consolaro A, Giancane G, Schiappapietra B, Dav\u00ec S, Calandra S, Lanni S, et al. Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2016;14:23 (BioMed Central).","journal-title":"Pediatr Rheumatol Online J."},{"key":"763_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-018-1780-z","volume":"20","author":"J Swart","year":"2018","unstructured":"Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva E, et al. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther. 2018;20:285 (BioMed Central).","journal-title":"Arthritis Res Ther."},{"key":"763_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13075-020-02167-2","volume":"22","author":"G Giancane","year":"2020","unstructured":"Giancane G, Swart JF, Castagnola E, Groll AH, Horneff G, Huppertz H-I, et al. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Arthritis Res Ther. 2020;22:71 (BioMed Central).","journal-title":"Arthritis Res Ther"},{"key":"763_CR17","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1093\/rheumatology\/keaa733","volume":"60","author":"JW van Straalen","year":"2021","unstructured":"van Straalen JW, Giancane G, Amazrhar Y, Tzaribachev N, Lazar C, Uziel Y, et al. A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis. Rheumatology. 2021;60:2896\u2013905 (Oxford Academic).","journal-title":"Rheumatology"},{"key":"763_CR18","doi-asserted-by":"publisher","unstructured":"van Straalen JW, Krol RM, Giancane G, Panaviene V, Ailioaie LM, Dole\u017ealov\u00e1 P, et al. Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use. Rheumatology (Oxford). 2022;61(5):2104\u201312. https:\/\/doi.org\/10.1093\/rheumatology\/keab678.","DOI":"10.1093\/rheumatology\/keab678"},{"key":"763_CR19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1136\/adc.2010.188946","volume":"96","author":"N Ruperto","year":"2011","unstructured":"Ruperto N, Martini A. Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO). Arch Dis Child. 2011;96:596\u2013601 (BMJ Publishing Group Ltd).","journal-title":"Arch Dis Child."},{"key":"763_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00296-018-3944-1","volume":"38","author":"F Bovis","year":"2018","unstructured":"Bovis F, Consolaro A, Pistorio A, Garrone M, Scala S, Patrone E, et al. Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology. Rheumatol Int. 2018;38:5\u201317 (Springer Verlag).","journal-title":"Rheumatol Int"},{"key":"763_CR21","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3899\/jrheum.100930","volume":"38","author":"G Filocamo","year":"2011","unstructured":"Filocamo G, Consolaro A, Schiappapietra B, Dalpr\u00e0 S, Lattanzi B, Magni-Manzoni S, et al. A new approach to clinical care of juvenile idiopathic arthritis: the Juvenile Arthritis Multidimensional Assessment Report. J Rheumatol. 2011;38:938\u201353.","journal-title":"J Rheumatol"},{"key":"763_CR22","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/art.41879","volume":"73","author":"C Trincianti","year":"2021","unstructured":"Trincianti C, Van Dijkhuizen EHP, Alongi A, Mazzoni M, Swart JF, Nikishina I, et al. Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis. Arthritis Rheumatol (Hoboken, NJ). 2021;73:1966\u201375.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)."},{"key":"763_CR23","first-page":"1","volume":"23","author":"J Kang","year":"2016","unstructured":"Kang J, Chan W, Kim M-O, Steiner PM. Practice of causal inference with the propensity of being zero or one: assessing the effect of arbitrary cutoffs of propensity scores. Commun Stat Appl Methods. 2016;23:1\u201320 (NIH Public Access).","journal-title":"Commun Stat Appl Methods"},{"key":"763_CR24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat Wiley-Blackwell. 2011;10:150\u201361.","journal-title":"Pharm Stat Wiley-Blackwell"},{"key":"763_CR25","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1093\/rheumatology\/key424","volume":"58","author":"S Hawley","year":"2019","unstructured":"Hawley S, Ali MS, Cordtz R, Dreyer L, Edwards CJ, Arden NK, et al. Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data. Rheumatology (Oxford). 2019;58:1168\u201375 (Oxford University Press).","journal-title":"Rheumatology (Oxford)."},{"key":"763_CR26","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1093\/rheumatology\/keaa044","volume":"59","author":"A Sarmanova","year":"2020","unstructured":"Sarmanova A, Doherty M, Kuo C, Wei J, Abhishek A, Mallen C, et al. Statin use and risk of joint replacement due to osteoarthritis and rheumatoid arthritis: a propensity-score matched longitudinal cohort study. Rheumatology. 2020;59:2898\u2013907 (Oxford Academic).","journal-title":"Rheumatology"},{"key":"763_CR27","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1136\/annrheumdis-2015-207784","volume":"75","author":"S Kubo","year":"2016","unstructured":"Kubo S, Nakayamada S, Nakano K, Hirata S, Fukuyo S, Miyagawa I, et al. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. Ann Rheum Dis. 2016;75:1321\u20137 (BMJ Publishing Group Ltd).","journal-title":"Ann Rheum Dis"},{"key":"763_CR28","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1093\/rheumatology\/kez655","volume":"59","author":"J-F Chen","year":"2020","unstructured":"Chen J-F, Hsu C-Y, Yu S-F, Ko C-H, Chiu W-C, Lai H-M, et al. The impact of long-term biologics\/target therapy on bone mineral density in rheumatoid arthritis: a propensity score-matched analysis. Rheumatology (Oxford). 2020;59:2471\u201380 (Oxford University Press).","journal-title":"Rheumatology (Oxford)"},{"key":"763_CR29","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1007\/s10067-019-04581-7","volume":"38","author":"N Takahashi","year":"2019","unstructured":"Takahashi N, Kojima T, Kida D, Kaneko A, Hirano Y, Fujibayashi T, et al. Concomitant methotrexate has little effect on clinical outcomes of abatacept in rheumatoid arthritis: a propensity score matching analysis. Clin Rheumatol Springer. 2019;38:2451\u20139.","journal-title":"Clin Rheumatol Springer"},{"key":"763_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30:377\u201399 (John Wiley & Sons, Ltd).","journal-title":"Stat Med"},{"key":"763_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13063-018-3108-3","volume":"20","author":"L Clifton","year":"2019","unstructured":"Clifton L, Clifton DA. The correlation between baseline score and post-intervention score, and its implications for statistical analysis. Trials. 2019;20:43 (BioMed Central).","journal-title":"Trials."},{"key":"763_CR32","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41409-019-0679-x","volume":"55","author":"J Gauthier","year":"2020","unstructured":"Gauthier J, Wu QV, Gooley TA. Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians. Bone Marrow Transplant. 2020;55:675\u201380 (Nature Publishing Group).","journal-title":"Bone Marrow Transplant"},{"key":"763_CR33","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https:\/\/www.R-project.org\/. 2019."},{"key":"763_CR34","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ophtha.2020.08.024","volume":"128","author":"V Rypdal","year":"2021","unstructured":"Rypdal V, Glerup M, Songstad NT, Bertelsen G, Christoffersen T, Arnstad ED, et al. Uveitis in Juvenile Idiopathic Arthritis: 18-Year Outcome in the Population-based Nordic Cohort Study. Ophthalmology. 2021;128:598\u2013608 (Elsevier Inc).","journal-title":"Ophthalmology."},{"key":"763_CR35","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/rheumatology\/kes373","volume":"52","author":"J Anink","year":"2013","unstructured":"Anink J, Otten MH, Prince FHM, Hoppenreijs EPAH, Wulffraat NM, Swart JF, et al. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register. Rheumatology (Oxford). 2013;52:712\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"763_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00296-009-0942-3","volume":"30","author":"M Halbig","year":"2009","unstructured":"Halbig M, Horneff G. Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept. Rheumatol Int. 2009;30:229\u201338 (Springer).","journal-title":"Rheumatol Int"},{"key":"763_CR37","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1093\/rheumatology\/ker103","volume":"50","author":"K Sevcic","year":"2011","unstructured":"Sevcic K, Orban I, Brodszky V, Bazso A, Balogh Z, Poor G, et al. Experiences with tumour necrosis factor- inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry. Rheumatology. 2011;50:1337\u201340 (Oxford Academic).","journal-title":"Rheumatology"},{"key":"763_CR38","doi-asserted-by":"crossref","unstructured":"Bergman M, Patel P, Chen N, Jing Y, Saffore CD. Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States. Rheumatol Ther. Springer; 2020;1\u201310.","DOI":"10.1007\/s40744-020-00256-x"},{"key":"763_CR39","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1007\/s10067-016-3439-y","volume":"35","author":"D Windschall","year":"2016","unstructured":"Windschall D, Horneff G. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis. Clin Rheumatol. 2016;35:2925\u201331 (Springer).","journal-title":"Clin Rheumatol"},{"key":"763_CR40","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","volume":"18","author":"G Horneff","year":"2016","unstructured":"Horneff G, Klein A, Klotsche J, Minden K, Huppertz H-I, Weller-Heinemann F, et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther. 2016;18:272 (BioMed Central).","journal-title":"Arthritis Res Ther."},{"key":"763_CR41","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00296-014-3103-2","volume":"35","author":"C Gim\u00e9nez-Roca","year":"2015","unstructured":"Gim\u00e9nez-Roca C, Iglesias E, Torrente-Segarra V, Bou R, S\u00e1nchez-Manubens J, Calzada-Hern\u00e1ndez J, et al. Efficacy and safety of TNF-alpha antagonists in children with juvenile idiopathic arthritis who started treatment under 4 years of age. Rheumatol Int. 2015;35:323\u20136 (Springer).","journal-title":"Rheumatol Int"},{"key":"763_CR42","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/cei.12782","volume":"184","author":"HM Walters","year":"2016","unstructured":"Walters HM, Pan N, Lehman TJA, Adams A, Kalliolias GD, Zhu YS, et al. The impact of disease activity and tumour necrosis factor-\u03b1 inhibitor therapy on cytokine levels in juvenile idiopathic arthritis. Clin Exp Immunol. 2016;184:308\u201317 (Wiley-Blackwell).","journal-title":"Clin Exp Immunol"},{"key":"763_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1874312901913010001","volume":"13","author":"E Alexeeva","year":"2019","unstructured":"Alexeeva E, Dvoryakovskaya T, Denisova R, Sleptsova T, Isaeva K, Chomahidze A, et al. Comparative Efficacy of Adalimumab and Etanercept in Children with Juvenile Idiopathic Arthritis Under 4 Years of Age Depending on Active Uveitis. Open Rheumatol J. 2019;13:1\u20138.","journal-title":"Open Rheumatol J"},{"key":"763_CR44","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1136\/annrheumdis-annrheumdis-2014-206747","volume":"75","author":"J Klotsche","year":"2016","unstructured":"Klotsche J, Niewerth M, Haas J-P, Huppertz H-I, Zink A, Horneff G, et al. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Ann Rheum Dis. 2016;75:855\u201361 (BMJ Publishing Group Ltd).","journal-title":"Ann Rheum Dis."},{"key":"763_CR45","doi-asserted-by":"publisher","unstructured":"Doeleman MJH, van Maarseveen EM, Swart JF. Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2019;58(10):1839\u201349. https:\/\/doi.org\/10.1093\/rheumatology\/kez030.","DOI":"10.1093\/rheumatology\/kez030"},{"key":"763_CR46","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrrheum.2014.4","volume":"10","author":"LLH de Lalouvi\u00e8re","year":"2014","unstructured":"de Lalouvi\u00e8re LLH, Ioannou Y, Fitzgerald M. Neural mechanisms underlying the pain of juvenile idiopathic arthritis. Nat Rev Rheumatol. 2014;10:205\u201311 (Nature Publishing Group).","journal-title":"Nat Rev Rheumatol"},{"key":"763_CR47","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S2352-4642(19)30027-6","volume":"3","author":"A Consolaro","year":"2019","unstructured":"Consolaro A, Giancane G, Alongi A, van Dijkhuizen EHP, Aggarwal A, Al-Mayouf SM, et al. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. Lancet Child Adolesc Heal. 2019;3:255\u201363.","journal-title":"Lancet Child Adolesc Heal"},{"key":"763_CR48","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/rheumatology\/kez048","volume":"58","author":"L Kearsley-Fleet","year":"2019","unstructured":"Kearsley-Fleet L, Vicente Gonz\u00e1lez L, Steinke D, Davies R, De Cock D, Baildam E, et al. Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). 2019;58:1453 (Oxford University Press).","journal-title":"Rheumatology (Oxford)."},{"key":"763_CR49","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ajo.2014.11.007","volume":"159","author":"AJW Haasnoot","year":"2015","unstructured":"Haasnoot AJW, van Tent-Hoeve M, Wulffraat NM, Schalij-Delfos NE, Los LI, Armbrust W, et al. Erythrocyte Sedimentation Rate as Baseline Predictor for the Development of Uveitis in Children With Juvenile Idiopathic Arthritis. Am J Ophthalmol. 2015;159:372-377.e1 (Elsevier).","journal-title":"Am J Ophthalmol"},{"key":"763_CR50","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jclinepi.2007.07.011","volume":"61","author":"PC Austin","year":"2008","unstructured":"Austin PC. The performance of different propensity-score methods for estimating relative risks. J Clin Epidemiol. 2008;61:537\u201345.","journal-title":"J Clin Epidemiol"},{"key":"763_CR51","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011;46:399 (Taylor & Francis).","journal-title":"Multivariate Behav Res"},{"key":"763_CR52","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.3346\/jkms.2018.33.e213","volume":"33","author":"H-S Kim","year":"2018","unstructured":"Kim H-S, Lee S, Kim JH. Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records. J Korean Med Sci. 2018;33:e213 (Korean Academy of Medical Sciences).","journal-title":"J Korean Med Sci."}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-022-00763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-022-00763-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-022-00763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T01:14:43Z","timestamp":1668647683000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-022-00763-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["763"],"URL":"https:\/\/doi.org\/10.1186\/s12969-022-00763-x","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,14]]},"assertion":[{"value":"31 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Pharmachild and all participating centers obtained approval from their respective ethics committees and were conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent\/assent based on existing national regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AC reports speaking fees from AbbVie and Pfizer and a research grant from Pfizer. NR has received honoraria for consultancies or speaker bureaus from the following pharmaceutical companies in the past 3\u00a0years: 2 Bridge, Amgen, AstraZeneca, Aurinia, Bayer, Brystol Myers and Squibb, Celgene, inMed, Cambridge Healthcare Research, Domain Therapeutic, EMD Serono, Glaxo Smith Kline, Idorsia, Janssen, Eli Lilly, Novartis, Pfizer, Sobi, UCB. All other authors declare no conflict of interest for this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}